Switch to:
Also traded in: Germany, Switzerland

Latest Guru Trades with HEB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:OTCPK:CLCS, OTCPK:STLT, OTCPK:PPCH, NAS:WINT, OTCPK:BLUSF, OTCPK:AYTU, OTCPK:SARSF, OTCPK:CRYO, OTCPK:WLDFF, NAS:SNGX, OTCPK:RVVTF, OTCPK:ENUM, OTCBB:DDRT, OTCPK:TQURF, OTCPK:BITRF, AMEX:IMUC, NAS:RXII, OTCPK:VRTHF, OTCPK:CRRTF, OTCPK:ATBPF » details
Traded in other countries:HXB1.Germany, HEB.Switzerland,
Hemispherx Biopharma Inc is a specialty pharmaceutical company. It is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.

Hemispherx Biopharma Inc is a Delaware Corporation founded in the early 1970s. The Company is a specialty pharmaceutical company. It is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Since its inception, it has established a foundation of laboratory, pre-clinical and clinical data with respect to the development of natural interferon and nucleic acids to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain chronic diseases. The Company owns and operates a 43,000 sq. ft. manufacturing facility in New Brunswick, NJ that produces Alferon and Ampligen. The Company operates in one segment, which performs research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's primary pharmaceutical product platform consists of its experimental compound, Ampligen, its FDA approved natural interferon product, Alferon N Injection and, its experimental liquid natural interferon for oral administration, Alferon LDO (Low Dose Oral). As of December 31, 2013, the Company had 25 patents. Its potential competitors are among the pharmaceutical companies in the world, are well known to the public and the medical community, and have substantially greater financial resources, product development, and manufacturing and marketing capabilities. The Company is subject to various federal, state and local laws, regulations and recommendations relating to such matters as safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use of and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its research work.

Ratios

vs
industry
vs
history
PB Ratio 0.73
HEB's PB Ratio is ranked higher than
95% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. HEB: 0.73 )
Ranked among companies with meaningful PB Ratio only.
HEB' s PB Ratio Range Over the Past 10 Years
Min: 0.6  Med: 1.83 Max: 13.74
Current: 0.73
0.6
13.74
PS Ratio 100.00
HEB's PS Ratio is ranked lower than
82% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. HEB: 100.00 )
Ranked among companies with meaningful PS Ratio only.
HEB' s PS Ratio Range Over the Past 10 Years
Min: 44.49  Med: 234 Max: 2630.77
Current: 100
44.49
2630.77
Current Ratio 3.84
HEB's Current Ratio is ranked lower than
53% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. HEB: 3.84 )
Ranked among companies with meaningful Current Ratio only.
HEB' s Current Ratio Range Over the Past 10 Years
Min: 1.36  Med: 5.15 Max: 44.82
Current: 3.84
1.36
44.82
Quick Ratio 3.84
HEB's Quick Ratio is ranked lower than
51% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. HEB: 3.84 )
Ranked among companies with meaningful Quick Ratio only.
HEB' s Quick Ratio Range Over the Past 10 Years
Min: 1.36  Med: 4.92 Max: 44.19
Current: 3.84
1.36
44.19
Days Inventory 385.33
HEB's Days Inventory is ranked lower than
89% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. HEB: 385.33 )
Ranked among companies with meaningful Days Inventory only.
HEB' s Days Inventory Range Over the Past 10 Years
Min: 67  Med: 270 Max: 389.91
Current: 385.33
67
389.91
Days Payable 308.54
HEB's Days Payable is ranked higher than
89% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. HEB: 308.54 )
Ranked among companies with meaningful Days Payable only.
HEB' s Days Payable Range Over the Past 10 Years
Min: 277.06  Med: 417.31 Max: 808.75
Current: 308.54
277.06
808.75

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -14.10
HEB's 3-Year Average Share Buyback Ratio is ranked lower than
59% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. HEB: -14.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HEB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.7  Med: -14.1 Max: -4.9
Current: -14.1
-25.7
-4.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.85
HEB's Price-to-Net-Cash is ranked higher than
70% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: 5.89 vs. HEB: 3.85 )
Ranked among companies with meaningful Price-to-Net-Cash only.
HEB' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.06  Med: 8.52 Max: 191.38
Current: 3.85
1.06
191.38
Price-to-Net-Current-Asset-Value 2.78
HEB's Price-to-Net-Current-Asset-Value is ranked higher than
79% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. HEB: 2.78 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
HEB' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.01  Med: 7.59 Max: 154.17
Current: 2.78
1.01
154.17
Price-to-Tangible-Book 0.77
HEB's Price-to-Tangible-Book is ranked higher than
97% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. HEB: 0.77 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
HEB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.71  Med: 5.55 Max: 154.17
Current: 0.77
0.71
154.17
Price-to-Median-PS-Value 0.43
HEB's Price-to-Median-PS-Value is ranked higher than
86% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. HEB: 0.43 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HEB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 0.98 Max: 11.61
Current: 0.43
0.15
11.61
Earnings Yield (Greenblatt) % -238.19
HEB's Earnings Yield (Greenblatt) % is ranked lower than
97% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. HEB: -238.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HEB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -312.5  Med: 396.7 Max: 2162.6
Current: -238.19
-312.5
2162.6

More Statistics

Revenue (TTM) (Mil) $0.10
EPS (TTM) $ -0.47
Beta-0.36
Short Percentage of Float0.60%
52-Week Range $0.39 - 2.64
Shares Outstanding (Mil)24.11

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) 0.04 0.24 0.48
EPS without NRI ($) 0.04 0.24 0.48
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for HEB

Headlines

Articles On GuruFocus.com
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-K/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Nov 08 2010 
Weekly CEO Sells Highlight: Hemispherx Biopharma Inc, ADESA Inc, Entergy Corp, and Danaher Corp. Aug 15 2010 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Aug 06 2010 
Hemispherx Biopharma Inc (HEB) CEO William A Carter buys 500,000 Shares Jul 01 2010 
Weekly CFO Buys Highlight: Wireless Telecom Group, ValueVision Media, American River Bankshares, Hem Dec 12 2009 
Hemispherx Biopharma Inc (HEB) CFO Charles Thomas Iii Bernhardt buys 2,000 Shares Dec 08 2009 

More From Other Websites
Why President Trump Wants To Transform The FDA – And What It Could Mean For Biotech Stocks Feb 23 2017
$1M deal: Hemispherx plans to sell stock, warrants Feb 03 2017
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Feb 03 2017
Hemispherx Biopharma, Inc. Announces $1 Million Registered Direct Offering Feb 02 2017
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Regulation FD Disclosure Feb 01 2017
Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to... Jan 26 2017
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jan 17 2017
Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to... Jan 11 2017
ETFs with exposure to Hemispherx Biopharma, Inc. : January 3, 2017 Jan 03 2017
HEMISPHERX BIOPHARMA INC Financials Dec 31 2016
ETFs with exposure to Hemispherx Biopharma, Inc. : December 19, 2016 Dec 19 2016
ETFs with exposure to Hemispherx Biopharma, Inc. : December 8, 2016 Dec 08 2016
Crystal Research Associates, LLC Issues Executive Informational Overview on Hemispherx Biopharma,... Dec 01 2016
ETFs with exposure to Hemispherx Biopharma, Inc. : November 23, 2016 Nov 23 2016
Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016 Nov 21 2016
Hemispherx 3Q Loss $2.9M or 13 Cents a Share (HEB) Nov 16 2016
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 15 2016
Hemispherx Biopharma Announces Financial Results in its Quarterly Report for the Nine Months Ended... Nov 14 2016
Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on November 15,... Nov 10 2016
Hemispherx Biopharma Featured in Corporate America News Magazine Special Report "Capturing the Power... Nov 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK